Arzu Onar‐Thomas

Novel mutations target distinct subgroups of medulloblastoma

Giles Robinson, Matthew Parker, Tanya A. Kranenburg et al. · Nature · 2012 · 853 citations · Full text

Medicine, Genetics, Oncology +17

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 502 citations · Full text

Medicine, Oncology, Pediatrics +16

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

Giles Robinson, Brent A. Orr, Gang Wu et al. · Journal of Clinical Oncology · 2015 · 460 citations · Full text

Medicine, Oncology, Pharmacology +15

Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma

Barbara S. Paugh, Alberto Broniscer, Chunxu Qu et al. · Journal of Clinical Oncology · 2011 · 323 citations · Full text

Medicine, Molecular Genetics, Oncology +17

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas et al. · Neuro-Oncology · 2017 · 320 citations · Full text

Medicine, Oncology, Pharmacology +17